ArticleDiscover oncology2025
Integrative analysis of efferocytosis- and invasion-related genes as potential biomarkers and therapeutic targets in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer remains a primary source of cancer-related mortality among females worldwide. This investigation sought to evaluate the distinctive expression patterns of genes linked to efferocytosis and invasion in breast cancer and their prognostic implications. Through bioinformatics analyses, a robust prognostic risk modelwas developed. Breast cancer datasets were procured and processed from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and GeneCards databases. Differential expression analysis was executed utilizing DESeq2, identifying genes with|logFC| >1 and p-value < 0.05. Efferocytosis-related genes and invasion-related genes were curated from GeneCards and PubMed, resulting in 127 overlapping genes. A prognostic risk model was developed utilizing univariate Cox regression, Least Absolute Shrinkage and Selection Operator regression, and multivariate Cox regression analyses. A sum of 7860 differentially expressed genes was ascertained in the TCGA-BRCA dataset, comprising 4130 elevated and 11,990 reduced expressions. Among them, 32 efferocytosis- and invasion-related genes exhibited differential expression, including ANO6 and PLGRKT. Univariate Cox regression pinpointed ANO6 and PLGRKT as significant prognostic markers. The Least Absolute Shrinkage and Selection Operator regression yielded the risk score formula: Risk score = ANO6 × (0.328) + PLGRKT × (-0.277). Kaplan-Meier survival analysis suggested a notable difference in survival outcomes between high-risk and low-risk cohorts (p-value < 0.01). Multivariate Cox analysis confirmed risk score, age, NStage subgroups N1-N3, and TStage subgroup T4 as statistically significant prognostic predictors. Functional enrichment analysis suggested that ANO6 and PLGRKT were implicated in biological processes like bleb assembly and the positive regulation of phagocytosis. Gene Set Enrichment Analysis identified notable pathway associations, encompassing the KEAP1/NFE2L2 Pathway and TP53 Regulation of Metabolic Genes. In conclusion, the developed prognostic risk model effectively predicts survival outcomes in patients with breast cancer, with ANO6 and PLGRKT being pivotal in tumor progression. These observations provide essential knowledge for therapeutic intervention strategies and enhanced clinical care in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.